<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="./PMC6594388/results/search/sars_covid_2/results.xml">
  <result pre="frequently (such as in the case of influenza virus) as" exact="pandemic" post="infections. Some of these viruses have been in the"/>
  <result pre="antibody, is recommended for prophylactic use in high-risk patients. The" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) is a newly emerging respiratory virus. The"/>
  <result pre="or antivirals have been yet approved for the treatment of" exact="MERS-CoV" post="in humans. It is clear that the discovery and"/>
  <result pre="of seasonal influenza viruses (H3N2var), and the emergence of the" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) highlight the serious and important need for"/>
  <result pre="therapies currently under development for treatment of influenza, RSV, and" exact="MERS-CoV" post="infections. We will briefly review drugs that have been"/>
  <result pre="of (A) influenza virus, (B) respiratory syncytial virus, and (C)" exact="Middle East respiratory syndrome" post="coronavirus, indicating where each therapeutic exerts its antiviral activity."/>
  <result pre="million people a year resulting in 12,000–56,000 deaths annually (" exact="Centers for Disease Control and Prevention," post="2018c). The economic burden is estimated to be in"/>
  <result pre="billions of dollars ( Putri et al., 2018). In addition," exact="pandemic" post="influenza outbreaks emerge at unpredictable intervals causing increased morbidity,"/>
  <result pre="treatment or chemoprophylaxis of currently circulating influenza A viruses (" exact="Centers for Disease Control and Prevention," post="2018a). Development of NAI started in the early 1970s"/>
  <result pre="body weight loss, and survival in mice infected with a" exact="pandemic" post="H1N1 influenza virus ( Tarbet et al., 2012) or"/>
  <result pre="virus resistant to NAI or in the event of a" exact="pandemic" post="(Toyama Chemical Co. Ltd). These conditions have been put"/>
  <result pre="Shahabi et al., 2017) including infants and young children (" exact="Centers for Disease Control and Prevention," post="2018b). Promising New Antiviral Candidates in the Pipeline In"/>
  <result pre="small molecules that bind to the F protein can block" exact="membrane" post="fusion and viral penetration, and subsequently inhibit RSV replication"/>
  <result pre="30 kb in length) belonging to the C lineage of" exact="Betacoronavirus" post="( Enjuanes et al., 2016; Wernery et al., 2017)."/>
  <result pre="occurred from the dromedary, the only known animal reservoir of" exact="MERS-CoV" post="( Wernery et al., 2017; Jordan et al., 2018;"/>
  <result pre="to the Arabic peninsula ( Park et al., 2019). Person-to-person" exact="transmission" post="has been well documented especially in health care workers"/>
  <result pre="the majority of cases have been observed in adults (" exact="Centers for Disease Control and Prevention," post="2017). Clinical features range from asymptomatic or mild to"/>
  <result pre="2013) and digestive symptoms including nausea, vomiting, and diarrhea (" exact="Centers for Disease Control and Prevention," post="2017) with some patients developing renal failure ( Bermingham"/>
  <result pre="( Bermingham et al., 2012; Jordan et al., 2018). The" exact="case fatality rate" post="worldwide is 34.6%, while in Saudi Arabia it is"/>
  <result pre="no licensed vaccines or therapeutics for prevention or treatment of" exact="MERS-CoV" post="infection and therapy is focused on supportive care to"/>
  <result pre="respiratory syndrome (SARS) outbreak in 2003 and the recent influenza" exact="pandemic" post="in 2009 ( Mo and Fisher, 2016). Furthermore, comprehensive"/>
  <result pre="that have been used for treatment of patients infected with" exact="MERS-CoV" post="include convalescent sera, corticosteroids, and/or antiviral therapeutics including interferons,"/>
  <result pre="patients (convalescent plasma) has shown beneficial effects in outbreaks of" exact="SARS" post="and influenza virus infections ( Al-Tawfiq et al., 2017)."/>
  <result pre="Due to the lack of clinical data demonstrating efficacy in" exact="MERS-CoV" post="infection, the use of CP is considered an investigational"/>
  <result pre="al., 2015). In preclinical studies, passive transfer of sera from" exact="MERS-CoV" post="immune camels to infected mice reduced weight loss and"/>
  <result pre="safety and effectiveness of CP therapy for patients infected with" exact="MERS-CoV" post="was recently published ( Arabi et al., 2015). In"/>
  <result pre="technology, polyclonal sera containing antibodies against the spike protein of" exact="MERS-CoV" post="were produced (SAB-301) and demonstrated to be effective in"/>
  <result pre="et al., 2015). In vitro, both mAbs potently neutralized the" exact="MERS-CoV" post="while in vivo studies in a mouse model of"/>
  <result pre="main strategies implemented in the clinics for the treatment of" exact="MERS-CoV" post="is the use of broadly acting antivirals although supportive"/>
  <result pre="such as interferon and ribavirin that show strong inhibition of" exact="MERS-CoV" post="in vitro have been used in the clinics with"/>
  <result pre="have been used in the management of patients with confirmed" exact="MERS-CoV" post="infection ( McIntosh, 2017). In a study using macaques,"/>
  <result pre="IFN-α2b and ribavirin staring at 8 h after infection with" exact="MERS-CoV" post="( Falzarano et al., 2013). The infected animals were"/>
  <result pre="also been used in combination therapies for the treatment of" exact="MERS-CoV" post="infection ( Shalhoub et al., 2015; Arabi et al.,"/>
  <result pre="al., 2019). A preclinical study in common marmosets infected with" exact="MERS-CoV" post="showed that treatment with a combination of lopinavir/ritonavir and"/>
  <result pre="more and better antiviral drugs to treat these respiratory infections." exact="MERS-CoV" post="recently emerged as a zoonotic respiratory infection and, therefore,"/>
  <result pre="to follow examples of antiviral therapies used during the recent" exact="SARS" post="outbreak; however, as described in this review, the approach"/>
  <result pre="the treatment of influenza virus, respiratory syncytial virus (RSV), and" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV). Therapeutic compound Infectious agent Mechanism(s) of action"/>
  <result pre="CR6261 Influenza Inhibits the binding of the virus to cell" exact="membrane" post="receptor 2a NCT02371668 CT-P27 Influenza Inhibits the binding of"/>
  <result pre="CT-P27 Influenza Inhibits the binding of the virus to cell" exact="membrane" post="receptor 2b NCT03511066 NCT02071914 MEDI8852 Influenza Inhibits the binding"/>
  <result pre="MEDI8852 Influenza Inhibits the binding of the virus to cell" exact="membrane" post="receptor 2a NCT03903718 NCT03028909 NCT02603952 MHAA4549A Influenza Inhibits the"/>
  <result pre="MHAA4549A Influenza Inhibits the binding of the virus to cell" exact="membrane" post="receptor 2 NCT01980966 NCT02623322 NCT02293863 Pimodivir Influenza Prevents viral"/>
  <result pre="RI-001 RSV Inhibits the binding of the virus to cell" exact="membrane" post="receptor 2 NCT00632463 REGN2222 RSV Viral fusion protein inhibitor"/>
  <result pre="ALS-008176 RSV Inhibits RSV polymerase 2 NCT02094365 NCT02673476 Convalescent plasma" exact="MERS-CoV" post="Inhibits virus entry to the target cells 2 NCT02190799"/>
  <result pre="Inhibits virus entry to the target cells 2 NCT02190799 SAB-301" exact="MERS-CoV" post="Inhibits virus entry to the target cells 1 NCT02788188"/>
  <result pre="the target cells 1 NCT02788188 REGN 3051 and REGN 3048" exact="MERS-CoV" post="Inhibits virus entry to the target cells 1 NCT03301090"/>
  <result pre="Inhibits virus entry to the target cells 1 NCT03301090 Ribavirin" exact="MERS-CoV" post="Interferes with the synthesis of viral mRNA 1 NCT02627378"/>
  <result pre="Z. A. ( 2017). A cohort-study of patients suspected for" exact="MERS-CoV" post="in a referral hospital in Saudi Arabia . J."/>
  <result pre="Memish Z. A. ( 2017). Update on therapeutic options for" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV). Expert Rev. Anti-Infect. Ther. 15, 269– 275."/>
  <result pre="2014). Ribavirin and interferon therapy in patients infected with the" exact="Middle East respiratory syndrome" post="coronavirus: an observational study . Int. J. Infect. Dis."/>
  <result pre="S. Al Harbi S. et al. ( 2018). Treatment of" exact="Middle East respiratory syndrome" post="with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial):"/>
  <result pre="and laboratory effects of convalescent plasma therapy for patients with" exact="Middle East respiratory syndrome" post="coronavirus infection: a study protocol . Springerplus 4: 709."/>
  <result pre="2013). Epidemiological, demographic, and clinical characteristics of 47 cases of" exact="Middle East respiratory syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study ."/>
  <result pre="Agents Chemother. 59, 1569– 1582. 10.1128/AAC.04623-14 , PMID: 25547360 collab:" exact="Centers for Disease Control and Prevention" post="( 2017). Middle East respiratory syndrome (MERS). Available at:"/>
  <result pre="25547360 collab: Centers for Disease Control and Prevention ( 2017)." exact="Middle East respiratory syndrome" post="(MERS). Available at: https://www.cdc.gov/coronavirus/mers/index.html (Accessed April 17, 2019). collab:"/>
  <result pre="syndrome (MERS). Available at: https://www.cdc.gov/coronavirus/mers/index.html (Accessed April 17, 2019). collab:" exact="Centers for Disease Control and Prevention" post="( 2018a). Influenza antiviral medications: summary for clinicians. Available"/>
  <result pre="for clinicians. Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed April 17, 2019). collab:" exact="Centers for Disease Control and Prevention" post="( 2018b). Respiratory syncytial virus (RSV). Available at: https://www.cdc.gov/rsv/clinical/index.html"/>
  <result pre="virus (RSV). Available at: https://www.cdc.gov/rsv/clinical/index.html (Accessed June 2016, 2019). collab:" exact="Centers for Disease Control and Prevention" post="( 2018c). Summary of the 107-2018 Influenza season. Available"/>
  <result pre="G. Jr. Hensley L. E. et al. . ( 2017)." exact="Middle East respiratory syndrome" post="and severe acute respiratory syndrome: current therapeutic options and"/>
  <result pre="Clinical and laboratory findings of the first imported case of" exact="Middle East respiratory syndrome" post="coronavirus to the United States . Clin. Infect. Dis."/>
  <result pre="2015). Ribavirin and interferon-alpha2b as primary and preventive treatment for" exact="Middle East respiratory syndrome" post="coronavirus: a preliminary report of two cases . Antivir."/>
  <result pre="( 2016). Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for" exact="Middle East respiratory syndrome" post=". Antivir. Ther. 21, 455– 459. 10.3851/IMP3002 , PMID:"/>
  <result pre="( 2016). Human polyclonal immunoglobulin G from transchromosomic bovines inhibits" exact="MERS-CoV" post="in vivo . Sci. Transl. Med. 8: 326ra321. 10.1126/scitranslmed.aaf1061"/>
  <result pre="Memish Z. A. Zumla A. I. Assiri A. ( 2013)." exact="Middle East respiratory syndrome" post="coronavirus infections in health care workers. N. Engl. J."/>
  <result pre="Fisher D. ( 2016). A review of treatment modalities for" exact="Middle East respiratory syndrome." post="J. Antimicrob. Chemother. 71, 3340– 3350. 10.1093/jac/dkw338 , PMID:"/>
  <result pre=", PMID: 27585965 Modjarrad K. ( 2016). Treatment strategies for" exact="Middle East respiratory syndrome" post="coronavirus. J. Virus Erad. 2, 1– 4. PMID: 26866060"/>
  <result pre="Z. A. Al-Tawfiq J. A. ( 2013). Therapeutic options for" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) – possible lessons from a systematic review"/>
  <result pre="coronavirus (MERS-CoV) – possible lessons from a systematic review of" exact="SARS-CoV" post="therapy . Int. J. Infect. Dis. 17, e792– e798."/>
  <result pre="and the role of peptides as potential therapeutic components for" exact="Middle East respiratory syndrome" post="(MERS): a review . J. Infect. Public Health 11,"/>
  <result pre=", PMID: 26511956 Omrani A. S. Shalhoub S. ( 2015)." exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV): what lessons can we learn? J. Hosp."/>
  <result pre="Y. M. et al. . ( 2018). Zoonotic origin and" exact="transmission" post="of Middle East respiratory syndrome coronavirus in the UAE"/>
  <result pre="et al. . ( 2018). Zoonotic origin and transmission of" exact="Middle East respiratory syndrome" post="coronavirus in the UAE . Zoonoses Public Health 65,"/>
  <result pre="Jung Y. et al. . ( 2019). Post-exposure prophylaxis for" exact="Middle East respiratory syndrome" post="in healthcare workers. J. Hosp. Infect. 101, 42– 46."/>
  <result pre="against spike protein in a novel humanized mouse model of" exact="MERS-CoV" post="infection . Proc. Natl. Acad. Sci. USA 112, 8738–"/>
  <result pre="A stem antibody MEDI8852 prevents and controls disease and limits" exact="transmission" post="of pandemic influenza viruses . J. Infect. Dis. 216,"/>
  <result pre="antibody MEDI8852 prevents and controls disease and limits transmission of" exact="pandemic" post="influenza viruses . J. Infect. Dis. 216, 356– 365."/>
  <result pre="E. Hui D. S. Perlman S. Zumla A. ( 2015)." exact="Middle East respiratory syndrome" post="– advancing the public health and research agenda on"/>
  <result pre="3966. 10.1016/j.vaccine.2018.05.057 , PMID: 29801998 Rabaan A. A. ( 2017)." exact="Middle East respiratory syndrome" post="coronavirus: five years later. Expert Rev. Respir. Med. 11,"/>
  <result pre="H. M. ( 2017). A review of candidate therapies for" exact="Middle East respiratory syndrome" post="from a molecular perspective . J. Med. Microbiol. 66,"/>
  <result pre="2015). IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat" exact="Middle East respiratory syndrome" post="coronavirus pneumonia: a retrospective study . J. Antimicrob. Chemother."/>
  <result pre="2012). Combinations of favipiravir and peramivir for the treatment of" exact="pandemic" post="influenza A/California/04/2009 (H1N1) virus infections in mice . Antiviral"/>
  <result pre="P. Belser J. A. et al. . ( 2009). Novel" exact="pandemic" post="influenza A(H1N1) viruses are potently inhibited by DAS181, a"/>
  <result pre="Wernery U. Lau S. K. Woo P. C. ( 2017)." exact="Middle East respiratory syndrome" post="(MERS) coronavirus and dromedaries. Vet. J. 220, 75– 79."/>
  <result pre="with dromedary immune serum in an experimental animal model for" exact="Middle East respiratory syndrome" post="coronavirus infection . J. Virol. 89, 6117– 6120. 10.1128/JVI.00446-15"/>
  <result pre="26868298 Zumla A. Hui D. S. Perlman S. ( 2015)." exact="Middle East respiratory syndrome." post="Lancet 386, 995– 1007. 10.1016/S0140-6736(15)60454-8 , PMID: 26049252"/>
 </snippets>
</snippetsTree>
